PeregoGGregisFRossiL, et al.Continuous-infusion and outpatient setting: a chance for patients, a challenge for hospital pharmacists. J Oncol Pharm Pract2020; 26: 1715–1720.
2.
San-MiguelJUsmaniSZMateosMV, et al.Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO). Haematologica2021; 106(6): 1725–1732. https://doi.org/10.3324/haematol.2019.243790
3.
Product Information: Darzalex®, Daratumumab Injection (Revised January 2021). Italy: Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Belgio
4.
LombardiJBoulinMDevauxM, et al.Safety of ninety-minute daratumumab infusion. J Oncol Pharm Pract2021; 27(5): 1080–1085.
5.
MateosMVNahiHLegiecW, et al.Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial [published correction appears in Lancet Haematol. 2020 Oct;7(10):e710]. Lancet Haematol2020; 7: e370–e380.
6.
ChariARodriguez-OteroPMcCarthyH, et al.Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label phase II study. Br J Haematol2021; 192: 869–878.
7.
KadingMBeckB. Cost analysis of daratumumab therapy: is there a cost benefit to using the recently approved subcutaneous product versus the IV product?J Oncol Pharm Pract2021; 27(4): 978–979.
8.
PonzettiCCancianiMFarinaM, et al.Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [published correction appears in Clinicoecon Outcomes Res. 2017 Jan 17;9:75]. Clinicoecon Outcomes Res2016; 8: 227–233. Published 2016 May 23.
9.
PassamontiFCattaneoCArcainiL, et al.Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol2020; 7: e737–e745.
10.
YuJOuyangWChuaMLK, et al.SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol2020; 6: 1108–1110.
11.
HamadehISMooreDCMartinA, et al.Transition from intravenous to subcutaneous daratumumab formulation in clinical practice, clinical lymphoma. Myeloma and Leukemia2021; 21(7): 470–475.
